HomeFileStructural heart disease

Structural heart disease

View Category

Mitral valve

ACC 2023 | TRILUMINATE Pivotal: Edge-to-Edge Treatment in Patients with Tricuspid Regurgitation

Tricuspid regurgitation is a common and impairing disease. Optimal medical therapy (OMT) is limited, valve surgery is...
solaci -
Learn More
Structural heart disease

ACC 2023 | TAVR in Low Risk Patients: 3-Year Outcomes

At present, transcatheter aortic valve replacement (TAVR) has become the gold standard in the US, regardless surgical...
solaci -
Learn More
Mitral valve

ACC 2023 | COAPT Study: 5 Year Followup after Transcatheter Repair of Secondary Mitral Regurgitation

The five year outcomes of the multicenter open label COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous...
solaci -
Learn More
Other

Intracardiac Echocardiography to Guide Watchman Left Atrial Appendix Closure: Safe and Effective?

Left atrial appendix closure (LAAC) has become a frequent intervention for stroke prevention in patients with atrial...
solaci -
Learn More
Other

FLASH Registry: Mechanical Thrombectomy with FlowTriever

Prospective registry of PTE patients who underwent FlowTriever, with 6 months of follow-up. The clinical relevance of interventional treatment...
solaci -
Learn More
Chronic Ischemic cardiopathy

Coronary Physiology after Aortic Valve Intervention

Impact of Aortic Valve Intervention on Coronary Flow Reserve Myocardial flow might be compromised in patients with severe...
solaci -
Learn More
Structural heart disease

TAVR and New Onset LBBB

The safety and efficacy of transcatheter aortic valve replacement (TAVR) is already established. However, it still poses...
solaci -
Learn More
Hypertrophic Cardiomyopathy

Resistant Obstructive Hypertrophic Cardiomyopathy: Myomectomy or Septal Ablation?

Approximately 70% of hypertrophic cardiomyopathies (HCM) are associated to a left ventricular outflow tract (LVOT) obstruction and...
solaci -
Learn More